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LungPoint—A New Approach to Peripheral Lesions
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Claus Peter Heussel, MD, PhD,† and Felix J. F. Herth, MD, PhD*
Introduction: Although flexible bronchoscopy is the least invasive
procedure for sampling, it is limited by its inability to reach lesions
in the peripheral segments of the lung. Biopsy success is further
compromised if the lesion is less than 30 mm in diameter or cannot
be seen on fluoroscopy. We wanted to explore whether a new
bronchoscopic navigation system could help access the peripheral
lung airways and enable lesion sampling.
Methods: The LungPoint system produced a virtual bronchoscopic
pathway indicating the bronchus into which the bronchoscope
should be advanced. Virtual bronchoscopic images were displayed
alongside and registered with actual bronchoscopic video. After
performing broncoscopy with a standard bronchoscope for first
examination, the thin bronchoscope was advanced to the target
bronchus under direct visualization without fluoroscopy. A pilot
study included consecutive patients at a tertiary teaching hospital
with pulmonary peripheral lesions (42 mm). Biopsies were taken
later.
Results: Study subjects included 25 patients (9 women and 16 men,
mean age 67 years) with 25 lesions (mean size 28 mm). Using this
navigation system, the bronchoscope could be advanced along the
planned route in all cases. In 14 of the cases (56%), the broncho-
scope could be advanced all the way to the lesion bronchus. The
planning time was a median of 5 minutes, and the median exami-
nation time was 15 minutes. A definitive diagnosis was possible in
20 cases (80%). One patient experienced a small pneumothorax
because of the biopsy that resolved without drainage. No other
complications occurred.
Conclusions: This navigation system is useful for bronchoscopy for
pulmonary peripheral lesions (NCT01067755).
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Solitary pulmonary nodule.
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Although lung cancer incidence is not closely tracked inEurope, in the United States, it is diagnosed in approxi-
mately 220,000 people each year and is the leading cause of
cancer death (incidence rate 72/100,000).1
There is an increasing need to evaluate and manage
pulmonary nodules and masses in chest medicine. As imag-
ing modalities advance, both computed tomography (CT) and
positron emission tomography (PET) are assuming a greater
role in lung cancer diagnosis. Imaging with CT is very useful
in the evaluation of lung cancer, but it lacks the sensitivity
and specificity necessary to definitively establish a diagnosis
on its own. Similarly, although PET is more sensitive than CT
in identifying lung lesions, there are too many false positives
to allow treatment decisions to be consistently made based on
PET imaging alone.2 As a result, although these imaging
modalities play a key role in the treatment decisions regard-
ing chemotherapy or surgical resection, often a tissue diag-
nosis will still be required.3
Bronchoscopy has been used to evaluate solitary pul-
monary nodules (SPNs) and masses for more than 30 years.
In patients with such nodules, the diagnostic procedure is
usually performed as transbronchial lung biopsy (TBBX)
under fluoroscopic guidance. This commonly performed pro-
cedure is associated with a low yield in SPNs smaller than 30
mm or lesions that are fluoroscopically invisible.4 The yield
depends not only on the size but also on the location of the
abnormality.5 Nodules that are too small to be visualized by
fluoroscopy during bronchoscopy pose a particular problem
and usually require more invasive, often surgical, biopsy
procedures.
If issues of diagnostic yield could be resolved, flexible
bronchoscopy would become the standard in the workup and
management of lung lesions. Therefore, new methods are
needed for bronchoscopic navigation and lesion localization,
which are independent of visualization by fluoroscopy but
still dependent on the technical skills of the bronchoscopist.
The first promising new technology in this regard was the
electromagnetic navigation system (InReach, superDimen-
sion Inc., Minneapolis, MN).
There remain some major challenges to the electromag-
netic technology. To plan the procedure, the electromagnetic
navigation bronchoscopy software is required, and the plan-
ning takes some time, up to 10 minutes in trained colleagues.
More significantly, the locatable guide is single use and costs
between US $700 and $1000, depending on the market,
usually without any kind of reimbursement.
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Ultrathin bronchoscopes (such as the BF-XP160F;
Olympus Medical, Tokyo, Japan), with external diameters of
2.8 mm, have been used in clinical practice since 2004 and
can be advanced to more peripheral bronchi than a standard
bronchoscope.
Because the bronchoscope can be advanced close to
peripheral lesions, subsequent guidance of the forceps is
easy.6 The challenge then becomes to identify the route to a
pulmonary peripheral lesion under direct vision within the
limited bronchoscopic examination time.7 It is essential to
review the CT images and confirm the bronchoscope’s route
before performing bronchoscopy. However, it is difficult to
obtain a three-dimensional understanding of the complicated
tracheobronchial tree based on axial images. Although virtual
bronchoscopy (VB) can reconstruct helical CT images to
display a three-dimensional rendering resembling the bron-
choscopic video,8 it has rarely been used in bronchoscopy for
pulmonary peripheral lesions.9
VB has some limitations in terms of the actual bron-
choscopic procedure.10 First, the bronchoscope is often ro-
tated while being advanced, creating an offset or shift be-
tween the observed actual image and the virtual image.
Bronchial branching includes many bifurcations into two
bronchi of similar sizes. Therefore, mistakes tend to be made
with regard to the correct bronchus into which the broncho-
scope will be advanced when there is a marked shift between
the observed and VB images. Second, the immediate match-
ing of the VB image corresponding to the observed bronchial
branching is difficult when the bronchoscope moves unex-
pectedly because of patient movements such as coughing. To
solve these problems, the LungPoint system displays the VB
images adjacent to the actual video, and an electronic path-
way is overlaid onto the endoscopic image. Once near the
target location, the identified lesion shape is overlaid onto the
airway wall on the actual and virtual bronchoscopic images,
providing further localization guidance for biopsy.
This article evaluates LungPoint’s usefulness as a bron-




The subjects were consecutive patients with PET-pos-
itive pulmonary peripheral lesions (42 mm) and a high
suspicion of lung cancer encountered at the Thoraxklinik
between July 2009 and December 2009. Lesions with a
CT-confirmed pure ground-glass opacity pattern and less than
15 mm were excluded because their diagnosis is considered
difficult when biopsy samples only a part of the lesion. The
local ethics committee approved this study protocol. All
subjects were given detailed descriptions of the examination
and were informed that a new approach was being evaluated.
Written informed consent was obtained from all subjects.
LungPoint
The LungPoint Virtual Bronchoscopic Navigation Sys-
tem (Broncus Technologies, Inc., Mountain View, CA) is a
computer-assisted image-based navigation software that en-
ables the bronchoscopist to navigate and localize a targeted area
of interest in the lung. The system requires thin-section volu-
metric CT scans. CT scan requirements for the system are
1.25-mm slice thickness with an interval spacing of 0.0625 mm
or less. Scans at total lung capacity (inspiratory breath-hold) are
preferred so that the smaller airways are expanded. The system
imports scans in standard Digital Imaging and Communications
in Medicine format either from a compact disk or across the
network. At our facility, the common parameters for the CT
scans were nonenhanced multi-detector computed tomography
(4-slice Siemens Volume Zoom, Forchheim, Germany), supine,
70 mAseff, 120 kV, collimation 4 1.25 mm, pitch 2, 1.25-mm
slice thickness [typically DLPw  127 mGy  cm, E  1.6
mSv according to International Commission on Radiologic Pro-
tection], 1-mm increment, B40f algorithm).
These were acquired from a full chest scan during
single breath-hold (automatic patient instruction for an in-
spiratory breath-hold) so that the entry of the lobar bronchus
involved by the lesion could be captured. Once the CT study
is imported using a compact disk or across the network, the
images are automatically analyzed by the LungPoint soft-
ware. This involves segmenting airways 3 mm and greater in
diameter and major vessels by calculating a centerline (cen-
tral axis) for each airway. Along with airway segmentation,
endoluminal renderings of the airway structure are modeled
to produce a virtual bronchoscopic view.
We defined the target lesion by placing a three-dimen-
sional spherical marker (from 3 to 30 mm in diameter) on a CT
image. The lesion can also be defined using tools to outline it on
the CT slice. In this case, the software automatically segments
the object in three dimensions. Once the target object is placed, the
software calculates up to three pathways through the airways to
reach it. These pathways are calculated to reach the points
closest to the target. Three-dimensional images of the airway
tree and target as well as the virtual bronchoscopic animation
enable assessment of the calculated pathways. The CT projec-
tions are also available and update as the animation progresses
through the airway toward the target.
During bronchoscopy, the navigation system displays two
main images: the live bronchoscopic video and the VB anima-
tion (Figure 1). The animation represents the pathway that was
selected during the planning process. An image-based synchro-
nization technique aligns the virtual images with the anatomy
seen in the live bronchoscopic video. A “navigator” or “copilot”
facilitates this process by advancing and adjusting (rotating or
shifting) the virtual bronchoscopic rendering. When the two
images are synchronized, the software calculates the position of
the bronchoscope in the airway and overlays the pathway to the
target on the actual bronchoscopic video image. Adjacent major
vessels as well as the target (once it is less than 30 mm away) are
overlaid on the airway wall.
Bronchoscopy
TBBX under general anesthesia was performed by a
trained bronchoscopist (R.E., F.H.) using a standard (BF-
Q180 or BF-1T180; Olympus Medical, Tokyo, Japan) and an
ultrathin (BF-XP160F; Olympus Medical) bronchoscope. All
samples were taken with 1.2-mm thin biopsy forceps (FB-
56D-I; Olympus Medical).
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After complete inspection of the bronchial tree, includ-
ing the subsegmental bronchi, the bronchoscope was navi-
gated using LungPoint as near as possible to the target. After
reaching the target or placing the scope in a wedge position,
the procedure continued with TBBX in the standard manner
without using fluoroscopy. Each lesion was biopsied a min-
imum of four times.
In case of an inconclusive diagnosis, additional test
were performed (e.g., CT-guided fine needle aspiration or
thoracoscopy).
Statistical Methods
Diagnostic sensitivity, specificity, and accuracy of the
LungPoint-guided transbronchial biopsies were calculated
using the standard definitions. Alpha was set at 0.05, and the
SPSS statistical software package was used for all analyses
(SPSS version 11.5; SPSS, Chicago, IL).
RESULTS
This feasibility trial included 25 subjects (9 women and
16 men) with a mean age of 67 years (SD 7.5 years; range,
52–83 years) and a mean lesion size of 28 mm (SD 0.7
mm; range, 18–42 mm).
Bronchoscopy was performed without complication in all
subjects; the mean planning time was 5 minutes (SD 61
seconds; range, 180–490 seconds), and the mean examination
time was 15 minutes (SD 2.5 minutes; range, 9–20 minutes).
Scope in to scope out time was 23 minutes (SD 3.2 minutes;
range, 18–35 minutes). The mean LungPoint navigation time
was 5 minutes (SD 83 seconds; range, 3–8 minutes). The
bronchial branchings on the VB images were in good accor-
dance with the actual branching in all cases. In 14 cases (56%),
the ultrathin bronchoscope could be advanced under LungPoint
guidance into the bronchus of the lesion, and the lesion was
visible by the scope. In these situations, further localization of
the lesion location was provided by an overlay on the airway
wall (Figure 2). For 11 lesions (44%), the ultrathin broncho-
scope could only be advanced up to one to two branchings
before the lesion location, although the bronchoscope followed
the planned route to that point. In these cases, the forceps were
advanced beyond the bronchoscope in the direction of the lesion,
and a biopsy was taken. In none of the cases, fluoroscopy was
used. The scope was held in a fixed position, and the different
biopsies were taken. With the standard scope, only six lesions
were visible by the scope, so all biopsies were done with the
small forceps.
Overall, a diagnosis was established in 20 of the 25
subjects (80%). Among the 20 subjects in whom transbron-
chial biopsy was diagnostic, 17 of the lesions were classified
as malignant (3 cases of squamous cell carcinoma, 11 cases
of adenocarcinoma, 1 case of non-small cell lung cancer, 1
case of small cell lung cancer, and 1 case of carcinoma with
large cells). Of the diagnostic biopsies, three lesions were
FIGURE 1. The predefined pathway to the target is a blue line.
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classified as benign (one sarcoidosis, one tuberculoma, and
one rheumatic nodule). The undiagnosed lesions included one
benign (harmatoma) and four malignant lesions. These five
cases and the estimated biopsy rheumatic nodule were con-
firmed by CT-guided needle aspiration (four cases) or surgi-
cal biopsies (two cases).
Successfully sampled lesions showed a mean short-axis
diameter of 28 mm (SD 6.5 mm; range, 19–41 mm). The
sensitivity, specificity, and negative and positive predicted
values for malignancy were 85%, 100%, 80%, and 57%.
The diagnostic rate depended on whether the lesion was
visible with the scope or not. The sampling success rate by
subject was 13 of 14 for reached lesions (93%) and 7 of 11 for
lesions (63%) beyond the view of the bronchoscope.
In a multivariate analysis, the yield did not depend on
the location of the lesion, histology, or other factors (proce-
dure time, planning time, sex, or age).
The mean number of specimens obtained from each
nodule was 4.2 (range, 4–6). Self-limited bleeding was
observed in one patient; severe bleeding did not occur. One
patient suffered from pneumothorax, but no intervention was
necessary. There were no other complications.
DISCUSSION
Bronchoscopy has been used to evaluate SPNs and
masses for more than 30 years. Patients with such nodules
frequently undergo transbronchial biopsy under fluoroscopic
guidance. However, endoscopic transbronchial biopsy often
fails to successfully sample lesions smaller than 30 mm or
lesions that are fluoroscopically invisible.4,12,13 Nodules too
small to be visualized by fluoroscopy usually require addi-
tional, often surgical, biopsy procedures.
Therefore, new methods for navigation and localization
are needed, which are independent of fluoroscopic visualiza-
tion and enhance the technical skills of the bronchoscopist.
Promising new technologies are CT-based electromagnetic
navigation techniques and endobronchial ultrasound (EBUS).
Several studies have reported on the efficacy and safety of
different techniques.14–20 With a diagnostic yield of 80% in
our trial, we were able to show quite similar results to the
established systems.
Asano et al.21 published their experience with another
prototype of a navigation system. The study subjects included
37 patients with 38 lesions. Using this system, an ultrathin
bronchoscope could be advanced into the planned route in
95% of the lesions. A diagnosis was possible for 82% of the
lesions.
LungPoint guidance can be performed safely in humans
and can easily be incorporated into a flexible bronchoscopy
practice. A similar pneumothorax rate compared with fluo-
roscopic-guided TBBX is shown in this trial. The system may
provide not only a reliable means for establishing a tissue
diagnosis but also open the door for endoscopic therapeutic
management in selected patients. Even though the technology
FIGURE 2. The target object is overlaid on the airway wall for guidance during biopsy.
Eberhardt et al. Journal of Thoracic Oncology • Volume 5, Number 10, October 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1562
seems very attractive and data are extremely encouraging,
more studies establishing yield and best applications are
needed.
The use of navigation techniques can push the diagnos-
tic yield of flexible bronchoscopy closer to the sensitivity
obtainable with transthoracic CT-guided procedures. Also,
pneumothorax, the major risk for transthoracic CT-guided
procedures, can be dramatically reduced (from 20–30%13 to
3–5%11). The proven comfort and safety of flexible bronchos-
copy and the recognized risks of these procedures confirm
bronchoscopy with navigation techniques or combined
EBUS/navigation as a viable alternative. The combination of
navigated bronchoscopy based on a virtual reality and real-
time control with the help of EBUS will not only expand the
diagnostic possibilities but in the future also provide more
therapeutic options for inoperable patients, such as flexible
endobronchial radio frequency ablation. The ultimate goal of
a reliable and minimally invasive biopsy of peripheral lung
lesions now seems feasible.
Some factors of our study need to be acknowledged. It
is important to recognize that the prevalence of malignant
lesions was high due to the inclusion criteria; therefore, the
same results may not be applicable in a more general and
unselected population. Another limitation is the small number
of patients. The trial was designed as a feasibility trial to
prove the concept. One of the major limitations of this study
is that no control group is diagnosed by the standard approach
of fluoroscopy. Fluoroscopy was not used for navigation,
because fluoroscopy is known to be unreliable in the identi-
fication of small lesions, and we wanted to ensure that we
would collect trial data that is specific for one intervention
only, namely LungPoint navigation. Maybe with the use of
fluoroscopy, the yield can be increased further. Also, data
supporting the use of multiple sampling techniques (needle,
bronchiolo alveolaer lavage, and brush) may improve the
yield. We limited this study to forceps biopsies for the sake of
time.
CONCLUSIONS
For smaller SPNs, navigated bronchoscopy with the
LungPoint system seems safe and effective. Navigation sup-
port may be more successful than fluoroscopic guidance in
sampling small SPNs, increasing the likelihood of a diagnosis
and decreasing the need for surgical biopsy. Further studies
potentially combining guided approaches with radial EBUS
are warranted.
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